TARA Protara Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1359931 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-48.3%
TTM EPS YoY-0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-57.4%
ROA-52.1%
ROIC (approx.)-57.3%
Asset turnover—
Leverage & solvency
Liabilities / assets9.9%
Debt / equity0.00x
Current ratio9.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-4.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $42.63M | $31.70M | $24.99M | $16.81M | $21.09M |
| SG&A expense | $21.92M | $17.45M | $18.62M | $20.74M | $26.40M |
| Operating income | -$64.55M | -$49.15M | -$43.61M | -$67.06M | -$47.49M |
| Interest expense | — | — | — | — | $0 |
| Pretax income | $57.35M | $44.56M | — | — | — |
| Net income | -$57.44M | -$44.60M | -$40.42M | -$65.95M | -$47.25M |
| EBITDA | -$64.19M | -$48.82M | -$43.27M | -$66.81M | -$47.37M |
| EPS (basic) | -1.34 | -2.17 | -3.57 | -5.86 | -4.21 |
| EPS (diluted) | -1.34 | -2.17 | -3.57 | -5.86 | -4.21 |
| Weighted avg. shares (diluted) | 42.84M | 20.59M | 11.33M | 11.26M | 11.23M |
| Balance sheet | |||||
| Cash & equivalents | $49.66M | $163.54M | $40.33M | $24.87M | $36.47M |
| Short-term investments | $105.90M | $7.49M | $25.99M | $60.24M | $55.51M |
| Current assets | $159.50M | $172.16M | $68.70M | $86.15M | $93.11M |
| PP&E, net | $759,000 | $1.03M | $1.30M | $1.59M | $1.72M |
| Goodwill | — | — | — | — | $29.52M |
| Total assets | $209.47M | $181.45M | $78.95M | $113.29M | $172.60M |
| Current liabilities | $10.94M | $10.96M | $6.15M | $5.74M | $4.30M |
| Short-term debt | — | — | — | — | $0 |
| Total liabilities | $13.06M | $14.32M | $10.63M | $11.21M | $10.68M |
| Shareholders' equity | $196.41M | $167.13M | $68.32M | $102.08M | $161.91M |
| Shares outstanding | 53.59M | 35.04M | 11.36M | 11.27M | 11.24M |
| Cash flow statement | |||||
| Operating cash flow | -$56.37M | -$35.81M | -$37.56M | -$26.46M | -$34.50M |
| Capital expenditure | $94,000 | $63,000 | $45,000 | $120,000 | $596,000 |
| Free cash flow | -$56.46M | -$35.87M | -$37.60M | -$26.58M | -$35.10M |
| Investing cash flow | -$139.49M | $19.16M | $53.11M | $14.95M | -$98.19M |
| Financing cash flow | $82.72M | $139.87M | -$91,000 | -$90,000 | -$228,000 |
| Depreciation & amortization | $362,000 | $332,000 | $341,000 | $248,000 | $117,000 |
| Stock-based compensation | $3.83M | $4.12M | $6.09M | $6.69M | $10.36M |
| Share buybacks | — | — | $91,000 | $90,000 | $228,000 |
Free plan shows the latest 5 periods; Pro shows all 14 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.